Reviva Pharmaceuticals Holdings Inc

12:15 PM - 12:30 PM (PDT), Tuesday, June 14, 2022
Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.
Ticker:
RVPH
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Brilaroxazine (RP5063)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Founder, President & CEO
Reviva Pharmaceuticals, Inc.